Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (7664)	1/6/2003 6:49:13 PM
From: scaram(o)uche	Respond to of 52153

I got to ALXN (nothing new that I heard, but I was somewhat distracted), by looping back through the "room-specific" links. That also worked for the Kessler Keynote and it's working now for CAT.

To: Icebrg who wrote (7664)	1/6/2003 8:34:31 PM
From: A.J. Mullen	Respond to of 52153

I attended MLNM. Nothing new there. Also went to CAT and heard a very low-key but very encouraging report. Talked of the latest deal with Dyax as well as the other recent ones. A X-licensing deal with Xoma is the only one in which there are net payments from CAt for IP. Estimates $30-40m per year from Abbott (3-4% royalty) Explained that with that income date for net-profitability is a matter of choice. Aims to be profitable AND have a good pipeline in 5yrs. Ashley